Point72 Hong Kong LTD Allovir, Inc. Transaction History

Point72 Hong Kong LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$3.26 - $7.06 $7,354 - $15,927	2,256 Added 94.39%	4,646 $18,000
Q1 2022 May 16, 2022	BUY	$6.75 - $13.52 $6,149 - $12,316	911 Added 61.6%	2,390 $16,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $19,138 - $38,439	1,479 New	1,479 $19,000
Q3 2021 Nov 15, 2021	SELL	$16.97 - $25.06 $2,070 - $3,057	-122 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$19.44 - $25.06 $6,376 - $8,219	-328 Reduced 72.89%	122 $2,000
Q1 2021 May 17, 2021	BUY	$20.81 - $45.5 $9,364 - $20,475	450 New	450 $11,000

44.4M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $933M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.